Cargando…

Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study

BACKGROUND: One of the main uses of seroprevalence studies it to evaluate vaccination programmes. In 1998, a programme of universal vaccination of preadolescents in schools with the hepatitis A vaccine was begun in Catalonia. The objective of this study was to investigate the prevalence and risk fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Domínguez, Àngela, Bruguera, Miquel, Plans, Pere, Espuñes, Jordi, Costa, Josep, Plasencia, Antoni, Salleras, Lluis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959232/
https://www.ncbi.nlm.nih.gov/pubmed/17610736
http://dx.doi.org/10.1186/1471-2334-7-73
_version_ 1782134624734937088
author Domínguez, Àngela
Bruguera, Miquel
Plans, Pere
Espuñes, Jordi
Costa, Josep
Plasencia, Antoni
Salleras, Lluis
author_facet Domínguez, Àngela
Bruguera, Miquel
Plans, Pere
Espuñes, Jordi
Costa, Josep
Plasencia, Antoni
Salleras, Lluis
author_sort Domínguez, Àngela
collection PubMed
description BACKGROUND: One of the main uses of seroprevalence studies it to evaluate vaccination programmes. In 1998, a programme of universal vaccination of preadolescents in schools with the hepatitis A vaccine was begun in Catalonia. The objective of this study was to investigate the prevalence and risk factors of hepatitis A virus infection (HAV) in a sample of the adult population of Catalonia in 2002 and to evaluate the changes with respect to a survey carried out in 1996. METHODS: The prevalence of HAV antibodies was determined by a third generation competitive immunometric assay in a representative sample of 1292 people aged >15 years. The association between the prevalence and different sociodemographic variables was determined by multiple logistic regression analysis. RESULTS: The standardized global prevalence of HAV antibodies in 2002 was 68.2%, increased with age (p < 0.0001) and was associated with being born outside Catalonia (OR: 1.75; 95% CI 1.11–2.76) and lower social class (OR: 1.14; 95% CI 1.05–1.25). Compared with the last survey carried out in 1996 the standardized global prevalence was lower (68.2% vs 77.8%; p < 0.0001) as was the prevalence in people under 45 years. CONCLUSION: The prevalence of the hepatitis A virus is decreasing in the adult population of Catalonia, especially in the younger age groups. The programme of vaccination of adolescents begun in 1998 to control the disease can provide indirect protection to the unvaccinated population.
format Text
id pubmed-1959232
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19592322007-08-30 Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study Domínguez, Àngela Bruguera, Miquel Plans, Pere Espuñes, Jordi Costa, Josep Plasencia, Antoni Salleras, Lluis BMC Infect Dis Research Article BACKGROUND: One of the main uses of seroprevalence studies it to evaluate vaccination programmes. In 1998, a programme of universal vaccination of preadolescents in schools with the hepatitis A vaccine was begun in Catalonia. The objective of this study was to investigate the prevalence and risk factors of hepatitis A virus infection (HAV) in a sample of the adult population of Catalonia in 2002 and to evaluate the changes with respect to a survey carried out in 1996. METHODS: The prevalence of HAV antibodies was determined by a third generation competitive immunometric assay in a representative sample of 1292 people aged >15 years. The association between the prevalence and different sociodemographic variables was determined by multiple logistic regression analysis. RESULTS: The standardized global prevalence of HAV antibodies in 2002 was 68.2%, increased with age (p < 0.0001) and was associated with being born outside Catalonia (OR: 1.75; 95% CI 1.11–2.76) and lower social class (OR: 1.14; 95% CI 1.05–1.25). Compared with the last survey carried out in 1996 the standardized global prevalence was lower (68.2% vs 77.8%; p < 0.0001) as was the prevalence in people under 45 years. CONCLUSION: The prevalence of the hepatitis A virus is decreasing in the adult population of Catalonia, especially in the younger age groups. The programme of vaccination of adolescents begun in 1998 to control the disease can provide indirect protection to the unvaccinated population. BioMed Central 2007-07-04 /pmc/articles/PMC1959232/ /pubmed/17610736 http://dx.doi.org/10.1186/1471-2334-7-73 Text en Copyright © 2007 Domínguez et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Domínguez, Àngela
Bruguera, Miquel
Plans, Pere
Espuñes, Jordi
Costa, Josep
Plasencia, Antoni
Salleras, Lluis
Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study
title Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study
title_full Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study
title_fullStr Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study
title_full_unstemmed Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study
title_short Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study
title_sort declining hepatitis a seroprevalence in adults in catalonia (spain): a population-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959232/
https://www.ncbi.nlm.nih.gov/pubmed/17610736
http://dx.doi.org/10.1186/1471-2334-7-73
work_keys_str_mv AT dominguezangela declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy
AT brugueramiquel declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy
AT planspere declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy
AT espunesjordi declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy
AT costajosep declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy
AT plasenciaantoni declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy
AT salleraslluis declininghepatitisaseroprevalenceinadultsincataloniaspainapopulationbasedstudy